← boardnext 2026-11-01
CRBP
Corbus Pharmaceuticals Inc.distress 7/10 · high distress / dilution risk$8.86+0%today-54% from 52w high
Lead: obesity · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$138M
Runway
1.9 yrs
Shares 1y
+51%
Price & events
+0.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.2%
1D
+0.7%
1W
+4.7%
1M
-13.3%
3M
+1.5%
6M
+0.8%
1Y
-84.6%
2Y
-79.1%
5Y
-76.7%
All
Overview
- Market Cap
- $164.16M
- Volume
- 18.00K
- 52 Week Range
- $7.38 – $19.36
- Total Shares
- 18.53M
- Float Shares
- 14.32M
- Short %
- 12.09%
- % Held by Insiders
- 1.08%
- % Held by Institutions
- 71.87%
- RVOL
- 0.05x
- Beta
- 2.56
Pipeline stages · 1 programs
CRB-701, Anti-PD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11-01 Estimated 50% readout ~2026-12-16 | Phase 1/2 | CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibodyfast track | Solid Tumor | — | recruiting |
| 2027-01-16 Estimated 50% readout ~2027-03-02 | Phase 1/2 | CRB-701, Anti-PD-1fast track | Solid Tumor, Adult | — | recruiting |
| 2026-07-02 | Phase 1 | CRB-913, Placebofast track | Obese But Otherwise Healthy Participants | 252 | active not recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 18
- early Q1 2027Guided 70%readoutPhase 1/2CRB-701 · Report CRB-701 + Keytruda combination data in 1L HNSCCSEC 8-K
- summer 2026Guided 40%readoutPhase 1CRB-913 · Completion of CANYON-1 Phase 1b dose-ranging study for CRB-913.SEC 8-K
- summer 2026Guided 40%trial initiationsecondaryPhase 3CRB-701 · Initiation of registrational study for CRB-701 in second-line HNSCC.SEC 8-K
- summer of 2026Guided 70%readoutPhase 1CRB-913 · Topline data from CANYON-1 Phase 1b trial expected.SEC 8-K
- summer 2026Guided 70%trial initiationsecondaryCRB-701 · Registrational study TEMPO-1 initiationSEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026trial initiationsecondaryPhase 3CRB-701 · Initiate registrational study for CRB-701 in HNSCCSEC 8-K
- ASCO 2026conferencedata presentationsecondaryPhase 1/2CRB-701 · Present updated monotherapy data from Phase 1/2 study at ASCO 2026SEC 8-K
- 2026-04-14enrollment completesecondaryPhase 1CRB-913 · Last patient first visit completed in CANYON-1 Phase 1b trial.SEC 8-K
- 2026-04-07fda agreementCRB-701 · Broad alignment on registration path for second-line HNSCC and cervical cancerSEC 8-K
- fourth quarter of 2025trial initiationsecondaryPhase 1CRB-913 · Commence Phase 1 dose-range finding studySEC 8-K
- fourth quarter of 2025readoutPhase 1/2CRB-701 · Dose optimization and RP2D determinationSEC 8-K
- Q3 2025readoutPhase 1CRB-913 · Phase 1 SAD/MAD study completionSEC 8-K
- Q1 2025readoutPhase 1CRB-701 · First data from dose escalation part of bridging Phase 1 trial for Nectin-4 ADC.SEC 8-K
- March 2025trial initiationsecondaryPhase 1CRB-913 · First participant dosing in Phase 1 SAD/MAD studySEC 8-K
- Q4 2024enrollment completesecondaryPhase 1CRB-701 · Expected completion of dose escalation phase in Phase 1 trial.SEC 8-K
- Q4 2024trial initiationsecondaryPhase 1CRB-601 · Initiate Phase 1 study.SEC 8-K
- Obesity Week 2024conferencedata presentationsecondaryCRB-913 · Pre-clinical data presented at Obesity Week 2024SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $35 (+298% upside) · 10 analysts
- 2026-06-23MizuhoOutperform
- 2026-06-17OppenheimerOutperform
- 2026-05-27WedbushOutperform
- 2026-05-26HC Wainwright & Co.Buy
- 2026-05-22MizuhoOutperform
- 2026-05-13JefferiesBuy
Competitors — obesity
- LLYELI LILLY & Co$1094.4B · D3
- AMGNAMGEN INC$195.4B · D3
- GPCRStructure Therapeutics Inc.$11.2B · D4
- RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
- MBXMBX Biosciences, Inc.$2.8B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- GUTSFRACTYL HEALTH, INC.$123M · D9
- VANIVivani Medical, Inc.$118M · D7
- MTVAMetaVia Inc.$8M · D7
- NONOFNOVO NORDISK A S— · D2
Recent news
- 2026-07-23(CRBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
- 2026-07-22Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
- 2026-07-21Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market - MarketWatch
- 2026-07-21Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market - MarketWatch
- 2026-07-17Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
- 2026-07-16Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
- 2026-07-13Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
- 2026-07-13Corbus Pharmaceuticals (CRBP) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares - High Growth Earnings - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.